Aims: Catheter ablation (CA) plays a central role in the management of electrical storm (ES). PAINESD and iVT are two validated scores commonly used to assess periprocedural risk in patients undergoing ventricular tachycardia (VT) ablation. This study aimed to evaluate the association between CA and mortality in ES patients stratified by PAINESD and iVT risk scores. Methods and results: We included 606 patients admitted for ES across four French centres. Risk was assessed using PAINESD and iVT scores. Mortality at 1 year was compared according to risk group and CA status. Baseline differences were adjusted using inverse probability of treatment weighting (IPTW) based on predefined clinical variables. Forty-one per cent of patients were classified as high-risk using the PAINESD score, and 39.4% using the iVT score. Catheter ablation was performed in 42.4% of the cohort, including 39.4% of hi-PAINESD and 35.5% of hi-iVT patients. After adjustment, CA was associated with lower 1-year mortality in both high- and low-risk groups (adjusted HR: 0.42 [95% CI: 0.26–0.66], P = 0.0002 for hi-PAINESD; 0.31 [0.18–0.53], P < 0.0001 for hi-iVT). Inverse probability of treatment weighting-weighted models yielded consistent results. In exploratory interaction analyses, the iVT score—but not PAINESD—identified high-risk patients who may derive earlier survival benefit from VT ablation. Conclusion: In patients with electrical storm, VT ablation was associated with lower 1-year mortality across both low- and high-risk profiles. The iVT score may help identify high-risk patients who derive earlier benefit from ablation.
Electrical storm represents an urgent challenge in electrophysiology. Despite the use of antiarrhythmic medications and catheter ablation, refractory ventricular arrhythmias may persist, prompting the use of neuromodulation. This approach has evolved over the years, facing initial challenges owing to the intricacies of the autonomic nervous system. Animal studies have significantly enhanced our understanding of this system, paving the way for human studies on sympathetic modulation, which gained momentum in the early 2000s and expanded notably in cardiology in the 2010s. Presently, a variety of techniques coexist and offer diverse alternatives. Additionally, there are promising avenues for development that are primarily explored in animal models. This review aims to shed light on the diverse approaches currently available in this field.
Following implantation/replacement of an implantable cardioverter-defibrillator, patients are legally subjected to variable lengths of driving restrictions based on the indication (1 and 3 months after primary and secondary prevention, respectively; 1 week after device replacement). To assess the incidence of ventricular arrhythmia during the theoretical driving restriction period in a large cohort of patients. Patients who underwent implantable cardioverter-defibrillator implantation for primary or secondary prevention or device replacement between 2015 and 2021 were included retrospectively. The primary endpoint was the occurrence of ventricular arrhythmia during the theoretical driving restriction period, as defined by guidelines. A total of 914 patients were analysed, including 654 first implantations (438 and 216 for primary and secondary prevention, respectively) and 260 device replacements. The primary outcome occurred in 2/438 patients (0.004%) during the 1-month period following device implantation for primary prevention and in 25/216 patients (11.5%) during the 3-month period following device implantation for secondary prevention; it did not occur in the 1-week period following device replacement. The monthly calculated risk of harm remained below the accepted threshold of 0.005% for each group. Primary prevention patients, such as those who have undergone device replacement, have a low risk of ventricular arrhythmia, which could lead to a reduction in their driving restriction period. Secondary prevention patients experienced a higher risk of recurrent ventricular arrhythmia, supporting the 3-month driving restriction period.
5 December 2025 in European Heart Journal: Acute Cardiovascular Care
Aims: Electrical storm (ES) is a highly heterogeneous condition with wide-ranging clinical presentations. The absence of standardized classification hampers risk stratification and limits effective multidisciplinary coordination. Objective: The aim of this study was to develop a classification system based on simple clinical characteristics and stratify 30-day mortality in patients with ES. Methods and results: Patients admitted to intensive care units for ES between 2010 and 2023 across four tertiary centres were retrospectively included. The five-stage STORM severity-response classification, based on treatment intensity during hospitalization, incorporated four clinically relevant parameters: signs of acute heart failure or haemodynamic instability, need for inotropes or vasopressors, use of advanced supportive therapies (including deep sedation) and renal replacement therapy, and implementation of mechanical circulatory support. The primary outcome was all-cause mortality at 30 days. A total of 788 patients were included. The cohort was predominantly male (84.3%), with a median age of 66.0 years (57.0–74.0). The majority had ischaemic cardiomyopathy (65.6%), with a median LVEF of 30.0% (20.0–45.0). According to the STORM classification, 421 patients (53.4%) were categorized as STORM-1, 45 (5.7%) as STORM-2, 86 (10.9%) as STORM-3, 220 (27.9%) as STORM-4 and 16 (2.0%) as STORM-5. Overall, 117 patients (14.8%) died within 30 days. A stepwise increase in 30-day mortality was observed across STORM stages – 5.0%, 6.7%, 20.9%, 30.5% and 50.0% for stages 1 through 5, respectively (P < 0.01). Conclusion: The STORM classification may facilitate standardized multidisciplinary management strategies and effectively stratifies 30-day mortality risk in patients with ES, ranging from 5% in stage 1% to 50% in stage 5. Further prospective studies are warranted to validate our findings.